Media ReleasesImpediMed

View All ImpediMed News


ImpediMed - AstraZeneca extends and increases Renal Contract


Key Highlights

* AstraZeneca extends its second contract for a Phase IIb trial, which is utilising SOZO® to measure fluid volume in patients with chronic kidney disease, by 3 months.
* In addition to extending the contract, AstraZeneca has increased the number of SOZO devices required by 23, taking the total number in this trial to 223.
* The extension and expansion of this trial will generate an estimated value of over $500k in additional revenue to be recognised in coming quarters.
* In total, over $5.5 million in contract value has been signed under the various AstraZeneca trial agreements, with just over $2.0 million remaining to be recognised in the coming quarters.
* The Company anticipates a range of 250-350 SOZO devices will remain under active contracts over the balance of the trials, as sites begin to complete their portion of testing.  

ImpediMed Limited (ASX.IPD), today announced the second contract extension and expansion of its SOZO Digital Health Platform used in clinical trials being conducted for AstraZeneca. The Phase II trial will use the SOZO devices to track patient fluid volume in an upcoming pharmaceutical study focused on chronic kidney disease. The study has been extended from 18 months to 21 months and the number of SOZO devices increased from 200 to 223.

In total, the contracts are expected to generate over $5.5 million in revenue across the trials. The Company recognised approximately $3.5 million in revenue under these contracts through 31 December 2021. The remainder of the revenue will be recognised throughout the second half of FY’22 and first half of FY’23.

The Company previously announced AstraZeneca is using SOZO to track patient fluid volume in two separate clinical trials. The first is focused on heart failure and chronic kidney disease and the second only on chronic kidney disease. A combined 434 SOZO devices have been leased across over 28 countries for both trials.  

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.